280 related articles for article (PubMed ID: 20367532)
1. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
2. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
3. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
4. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
5. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
6. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
8. Novel targeted therapies for prostate cancer.
Macfarlane RJ; Chi KN
Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
Ojemuyiwa MA; Madan RA; Dahut WL
Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
11. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
12. Emerging MEK inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2010 Jun; 15(2):203-23. PubMed ID: 20151845
[TBL] [Abstract][Full Text] [Related]
13. Anti-endothelin drugs in solid tumors.
Russo A; Bronte G; Rizzo S; Fanale D; Di Gaudio F; Gebbia N; Bazan V
Expert Opin Emerg Drugs; 2010 Mar; 15(1):27-40. PubMed ID: 20102289
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors to treat liver cancer.
Huynh H
Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
[TBL] [Abstract][Full Text] [Related]
16. SRC inhibitors in metastatic bone disease.
Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
[TBL] [Abstract][Full Text] [Related]
17. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
18. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
19. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
20. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
